HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR Panel's Parabens Review Leaning Toward Safe, But 'Insufficient Data' For Now

This article was originally published in The Rose Sheet

Executive Summary

Cosmetic Ingredient Review’s independent experts will continue to mull new safety information for parabens, as well as input from a P&G expert, but the panel is inclined to determine the preservatives safe as used in an assessment that could differ “significantly” from European conclusions. 

You may also be interested in...



CIR Recalculates Parabens Safety Margins; Will Expert Panel’s Confidence Be Shaken?

The Cosmetic Ingredient Review’s newly figured margins of safety for single- and multi-paraben use in cosmetic products are dramatically lower than previous MOSs that informed the Expert Panel’s 2008 “safe as used” conclusions. Whether the panel still deems the MOSs sufficiently protective is the question going into the group’s Sept. 24-25 meeting.

Cosmetic Preservatives Crisis Creeping Into CIR Program

If concerns about cosmetic preservatives are unfounded from a scientific standpoint, then the Cosmetic Ingredient Review Expert Panel should be in a position to set the record straight. However, data gaps have the group considering “insufficient data” findings in pending reviews of parabens and polyaminopropyl biguanide.

CIR Tables Review Of Preservative PHMB; Industry Maintains Data Is On The Way

The Cosmetic Ingredient Review Expert Panel tabled a draft final report for preservative polyaminopropyl biguanide June 5 to await promised sensitization and exposure data from industry. There is concern that an “insufficient data” decision could prompt reformulations with even more questionable alternatives in a market short on preservative options.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel